Drug profile

The FDA adverse-event record for Unspecified Fluid Therapy

29 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Unspecified Fluid Therapy. See the species affected, top reactions, and outcomes below.

29
adverse-event reports
44.8%
death-coded share
Dog
most-reported species
12
Lethargy (see also Central nervous system depression in Neurological) - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
29
Total Reports
13
Deaths Reported
44.8%
Death Rate

Active Ingredients

Unspecified Fluid Therapy

Administration Routes

UnknownIntravenousSubcutaneous

Species Affected

Dog 22
Cat 7

Most Affected Breeds

Domestic Shorthair 5
Retriever - Golden 2
Terrier - Airedale 2
Retriever - Labrador 2
Shiba Inu 1
Dachshund (unspecified) 1
Terrier - Yorkshire 1
Terrier (unspecified) 1
Boxer (German Boxer) 1
Poodle (unspecified) 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in Neurological) 12
Not eating 11
Death by euthanasia 9
Vomiting 8
Not himself/herself 7
Anorexia 6
Weight loss 6
Diarrhoea 6
Elevated serum alkaline phosphatase (ALP) 6
Lack of efficacy - NOS 6
Intentional misuse 6
Abnormal radiograph finding 6

Outcome Breakdown

Ongoing
12 (41.4%)
Euthanized
9 (31.0%)
Died
4 (13.8%)
Recovered/Normal
3 (10.3%)
Outcome Unknown
1 (3.4%)

Unspecified Fluid Therapy Adverse Event Insights

29 reports name Unspecified Fluid Therapy; 13 recorded a death outcome (44.8% of reported events, not a population-level mortality rate). Active ingredient: Unspecified Fluid Therapy. Administration routes: Unknown, Intravenous, Subcutaneous.

By species: Dog (22 reports), Cat (7 reports). By breed: Domestic Shorthair (5), Retriever - Golden (2), Terrier - Airedale (2).

Leading clinical signs: Lethargy (see also Central nervous system depression in Neurological) (12), Not eating (11), Death by euthanasia (9), Vomiting (8). Outcome, 29 coded reports: Ongoing leads at 41.4%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.